Trial Profile
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node- Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel
- Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 10 Dec 2019 Results assessing whether the addition of trastuzumab to adjuvant chemotherapy improve invasive disease free survival in patients with HER2 negative breast cancer were published in the Journal of Clinical Oncology
- 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium
- 05 May 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Aug 2017.